Skip to Main Content

Filter:

Emerging Strategies for Rheumatoid Arthritis

1 Results

Research Article
Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea
Clinical Therapeutics
Vol. 37Issue 8p1662–1676.e2Published online: August 1, 2015
- Min-Young Lee
- Sun-Kyeong Park
- Sun-Young Park
- Ji-Hye Byun
- Sang-Min Lee
- Su-Kyoung Ko
- and others
Cited in Scopus: 19
This study evaluated the cost-effectiveness of introducing tofacitinib, an oral Janus kinase inhibitor, to the treatment of Korean patients with rheumatoid arthritis (RA) and an inadequate response to conventional disease-modifying antirheumatic drugs.